Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia
In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia. Results from the Phase 2 trial were […]
